[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Quaid-e-Azam Medical College\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100643422","myo-inositol-alone-versus-myo-inositol-plus-alpha-lactalbumin-in-women-with-polycystic-ovary-syndrome-100643422",false,"NCT07629895","Myo-Inositol Alone Versus Myo-Inositol Plus Alpha-Lactalbumin in Women With Polycystic Ovary Syndrome","Comparison of Efficacy of Myo-Inositol Alone With Myo-Inositol Plus Alpha-Lactalbumin on Reproductive and Metabolic Parameters in Polycystic Ovarian Syndrome","MIALA-PCOS","Inclusion Criteria:\n\n* Female participants aged 18 to 35 years.\n* Diagnosed with polycystic ovary syndrome according to Rotterdam criteria.\n* Diagnosis of PCOS for at least 6 months before enrollment.\n* Willing to conceive.\n* Normal husband semen analysis.\n\nExclusion Criteria:\n\n* Pre-existing diabetes mellitus.\n* Thyroid dysfunction.\n* Hyperprolactinemia.\n* Cushing syndrome.\n* Congenital adrenal hyperplasia.\n* Androgen-secreting adrenal or ovarian tumors.\n* Conditions causing ovulatory dysfunction and\u002For hyperandrogenism other than PCOS.\n* Use of ovulation-induction agents, hormonal therapy, insulin sensitizers, or anti-androgens within the previous 12 weeks.\n* Morbid obesity (BMI ≥40 kg\u002Fm²).\n* Known cow milk protein allergy, hypersensitivity to study medications, or severe gastrointestinal malabsorption.\n* Hepatic, renal, or cardiovascular impairment.\n* Tubal factor infertility.\n* Endometriosis.\n* Structural uterine abnormality.\n* Male factor infertility.","FEMALE","18 Years","35 Years",{"count":21,"type":22},82,"ESTIMATED","INTERVENTIONAL",[25],"NA","Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting reproductive-aged women and is associated with menstrual irregularities, infertility, hyperandrogenism, obesity, and insulin resistance. Myo-inositol is commonly used as an insulin-sensitizing agent to improve reproductive and metabolic outcomes in women with PCOS. Alpha-lactalbumin may enhance the intestinal absorption and bioavailability of myo-inositol and potentially improve treatment response.\n\nThis randomized controlled trial aims to compare the efficacy of myo-inositol alone versus myo-inositol plus alpha-lactalbumin in women with PCOS. Eighty-two eligible women will be randomized to receive either myo-inositol alone or myo-inositol combined with alpha-lactalbumin for 12 weeks. The study will evaluate reproductive outcomes including spontaneous conception, menstrual regularity, hirsutism, and hormonal parameters, as well as metabolic outcomes including body mass index and insulin resistance.",[28],"Polycystic Ovary Syndrome (PCOS)",[30,31,32,33,34,35,36],"PCOS","Myo-Inositol","Alpha-Lactalbumin","Infertility","HOMA-IR","Reproductive Outcomes","Metabolic Parameters","NOT_YET_RECRUITING","2026-06-05",{"date":40,"type":41},"2026-06-09","ACTUAL",{"date":43,"type":22},"2026-09",{"date":45,"type":22},"2027-06",{"name":47,"class":48},"Quaid-e-Azam Medical College","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":49},"100600849","phase-2-comparison-of-zinc-and-probiotics-on-neonates-with-indirect-hyperbilirubinemia-undergoing-phototherapy-100600849","NCT07102836","COMPARISON OF ZINC AND PROBIOTICS ON NEONATES WITH INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY","COMPARATIVE EFFECTS OF ZINC AND PROBIOTICS ON NEONATAL INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY","ZIPP","Inclusion Criteria:\n\n* 1\\. Term or Near term neonates 2. Age \\\u003C7 days at enrollment 3. Bilirubin levels within phototherapy range according to NICE bilirubin threshold charts 4. No identifiable pathology 5. Tolerating oral feeds 6. Parental or Guardian written informed consent taken.\n\nExclusion Criteria:\n\n* 1\\. Positive sepsis screen or clinical signs of infection 2. Direct hyperbilirubinemia 3. Gastrointestinal malformations 4. Oral intolerance 5. Requiring mechanical ventilation 6. Congenital anomalies 7. Parental or Guardian refusal to participate in study","ALL","0 Days","28 Days",{"count":62,"type":22},110,[64],"PHASE2","Study will evaluate effects of oral zinc and probiotics supplementation in neonates who have indirect hyperbilirubinemia and are receiving phototherapy. Aim is to compare efficacy of these two drugs in clearing bilirubin and reducing duration of phototherapy. Neonates will be randomly assigned to receive either drug alongside phototherapy.",[67,68],"Indirect Hyperbilirubinemia","Neonatal",[70,71,72,73,74,75,76,77,67],"Zinc","Probiotics","Jaundice","Phototherapy","Neonates","Randomized Controlled Trial","Bilirubin","Enterohepatic Circulation","RECRUITING","2025-07-30",{"date":81,"type":41},"2025-08-05",{"date":83,"type":22},"2025-08-07",{"date":85,"type":22},"2026-05-07",{"name":47,"class":48},""]